Extra studies in progress suggest that ARV-825 may also be effective in boosting the response to estrogen deprivation (aromatase inhibition), another component of ordinary of treatment in ER+ breast cancer. For all circulation cytometry experiments, 10,000 cells per replicate were being analyzed,